PIII vs. AIRS, TOI, EUDA, DCGO, CORBF, XGN, QIPT, SERA, BMGL, and ATPC
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include AirSculpt Technologies (AIRS), Oncology Institute (TOI), EUDA Health (EUDA), DocGo (DCGO), Global Cord Blood (CORBF), Exagen (XGN), Quipt Home Medical (QIPT), Sera Prognostics (SERA), Basel Medical Group (BMGL), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry.
P3 Health Partners vs.
P3 Health Partners (NASDAQ:PIII) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
AirSculpt Technologies has lower revenue, but higher earnings than P3 Health Partners. AirSculpt Technologies is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
P3 Health Partners presently has a consensus target price of $16.25, indicating a potential upside of 113.53%. AirSculpt Technologies has a consensus target price of $3.75, indicating a potential downside of 9.86%. Given P3 Health Partners' stronger consensus rating and higher probable upside, research analysts plainly believe P3 Health Partners is more favorable than AirSculpt Technologies.
AirSculpt Technologies has a net margin of -4.13% compared to P3 Health Partners' net margin of -6.95%. AirSculpt Technologies' return on equity of 2.22% beat P3 Health Partners' return on equity.
AirSculpt Technologies received 6 more outperform votes than P3 Health Partners when rated by MarketBeat users. Likewise, 35.48% of users gave AirSculpt Technologies an outperform vote while only 31.25% of users gave P3 Health Partners an outperform vote.
7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 17.8% of P3 Health Partners shares are owned by company insiders. Comparatively, 76.6% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, P3 Health Partners had 3 more articles in the media than AirSculpt Technologies. MarketBeat recorded 3 mentions for P3 Health Partners and 0 mentions for AirSculpt Technologies. AirSculpt Technologies' average media sentiment score of 0.00 beat P3 Health Partners' score of -0.18 indicating that AirSculpt Technologies is being referred to more favorably in the news media.
P3 Health Partners has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, AirSculpt Technologies has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Summary
AirSculpt Technologies beats P3 Health Partners on 12 of the 18 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 5/23/2025 by MarketBeat.com Staff